VYNE vs. NXTC, KZR, MNOV, HOOK, PRTK, VERU, CYBN, IMAB, RAPT, and INCR
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include NextCure (NXTC), Kezar Life Sciences (KZR), MediciNova (MNOV), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), Veru (VERU), Cybin (CYBN), I-Mab (IMAB), RAPT Therapeutics (RAPT), and InterCure (INCR). These companies are all part of the "medical" sector.
VYNE Therapeutics (NASDAQ:VYNE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
VYNE Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
NextCure received 54 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 63.93% of users gave NextCure an outperform vote while only 58.54% of users gave VYNE Therapeutics an outperform vote.
In the previous week, NextCure had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 6 mentions for NextCure and 3 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.29 beat NextCure's score of 0.48 indicating that VYNE Therapeutics is being referred to more favorably in the media.
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.8% of VYNE Therapeutics shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NextCure has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,874.47%. NextCure's return on equity of -53.29% beat VYNE Therapeutics' return on equity.
VYNE Therapeutics presently has a consensus price target of $5.75, suggesting a potential upside of 126.38%. NextCure has a consensus price target of $6.00, suggesting a potential upside of 289.61%. Given NextCure's higher possible upside, analysts clearly believe NextCure is more favorable than VYNE Therapeutics.
VYNE Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Summary
NextCure beats VYNE Therapeutics on 10 of the 16 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
